Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial - Wikidata - awgldk - TriplyDB

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial

http://www.wikidata.org/entity/Q36934269

about

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome Clinical Results of Hypomethylating Agents in AML Treatment Therapy-related myeloid neoplasms - what have we learned so far?5-Aza-2'-deoxycytidine inhibited PDGF-induced rat airway smooth muscle cell phenotypic switching Established and emerging targeted therapies in the myelodysplastic syndromes.Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience.Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS.A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.Myelodysplastic syndromes: Contemporary review and how we treat.Demethylating Agents in the Treatment of Cancer Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.Epigenetic therapies in MDS and AML Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome.Current therapy of myelodysplastic syndromes Decitabine in the treatment of myelodysplastic syndromes.Targeting DNA methylation for epigenetic therapy.Leukaemogenesis: more than mutant genes Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.Clinical development of demethylating agents in hematology TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients The role of azacitidine in the management of myelodysplastic syndromes (MDS).New treatments for myelodysplastic syndromes Hypomethylating agents and other novel strategies in myelodysplastic syndromes.Demethylating agents in myeloid malignancies.The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes.Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients.

P2860

Q24622700-E4A9FA38-9735-4138-A890-CA9C6759CC0A Q24632949-F9AD648A-3098-4F7D-A971-C03EB019132C Q26743743-0DA96018-893D-46FD-A904-A7C943921B67 Q26745731-3430F353-DC63-4026-A7C9-BC4F2090C434 Q26749870-E778FAEA-A677-4C1C-B6D0-33C41F4A01E4 Q26796240-20F25A06-4B21-4D60-967C-AD23B8FE08D0 Q26829132-F5234093-CDF9-459D-A832-37C32054661A Q27022725-023388DE-B9BA-4CD0-86D5-D3419150CE0D Q28071318-944A823B-80BB-4433-9EDE-D9FC2939D70A Q28576398-E2EAD4AB-59A6-4DBD-B71D-0CD0B09DC7C9 Q30245476-CFA8464E-F418-4570-830C-3A9FFB4FA6F5 Q33392205-EF6370FD-F759-492D-A51E-A40064DD877E Q33396739-1CCF55C6-AE14-4DF3-933B-9F817F2525FB Q33402882-B5106D1C-958B-4F70-9F23-801CBC2951EC Q33429195-24008271-1D69-424F-8606-BBFD87035880 Q33678040-EB05460E-B0B2-4CE8-BE2A-964ACB104837 Q33841988-D55E3A1C-696D-4FC5-9DB3-9672A2A41704 Q33863567-EA3B7302-48E1-425F-A9EC-848F550EA78D Q33903052-A82235A1-3479-4684-93D9-FD9B2CD9B052 Q33995598-314484D1-88DD-48B3-8D3B-06D0E376267F Q33995610-60A59AB6-C9AB-46F8-9780-FC47D6D58E06 Q34013796-F492BF0E-2E2A-4CA2-B038-BA4542238286 Q34088403-43CFD609-AE7E-45A6-BBB5-5851347E3083 Q34258037-058F8C2F-CF21-40E3-AD6C-822EEF6FF203 Q34275371-2ABEF8B0-CF7B-4B02-808F-CD4F8EFA349A Q34350209-3BA47B53-1E6B-4E4E-84E6-B7E0F9295E9D Q34395179-E0A8B034-82E3-4079-9674-04FF6BB88CEA Q34398397-E48DDFC0-C0CF-47A0-8EA4-033DAB5E3EE4 Q34418429-55E64D13-E6D0-490B-9391-829DDA12ECA3 Q34549290-338413C4-C6A7-480A-A9E1-008D5B377FBB Q34667051-5B332BBC-9333-4EC3-9BA3-159CBE5C3D47 Q34847863-06DD216C-3184-4FD0-84CC-7DA8E8B7279E Q34979774-60D70C9C-8877-4E97-BE3F-8B4E01A43BB9 Q35043089-BD0E76E2-5CC1-45B6-A721-EF41498ACD60 Q35058556-B336A144-AF0F-43A7-BE41-B2038E5AFD6C Q35153059-1A22AED8-FBBE-4E47-A5F7-5EC8005BD8DF Q35183982-0944793C-D88A-4028-A8CE-770EA122CEC6 Q35202854-53343D26-910B-429D-8615-2F7D186979DD Q35265834-C3921552-A059-488D-AFC1-87BC8843D2FD Q36138278-31FDC440-BE18-4491-B3FC-4ABC64EF14BA

P2860

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial

http://www.wikidata.org/entity/Q36934269

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Multicenter study of decitabin ...... atient treatment (ADOPT) trial

@en

type

label

Multicenter study of decitabin ...... atient treatment (ADOPT) trial

@en

prefLabel

Multicenter study of decitabin ...... atient treatment (ADOPT) trial

@en

P1433

Q36934269-E82CDEE7-AC35-4493-A15E-7B7BC2FBD282

P1476

Q36934269-DA4D845E-9204-4E6E-8FC0-2D38D826D685

P2093

Q36934269-07A94478-1A9F-4FEC-B161-095DABAC06EA

Q36934269-2C2C121C-D31F-4F65-9607-6DB37BF48961

Q36934269-435BEC8C-00F2-402B-80D4-F69A4EEE1D4D

Q36934269-58DA49D6-7944-49A1-B391-701DFB6A7122

Q36934269-62346B63-10ED-4867-A21B-0ADCD30F07CE

Q36934269-81C08940-C019-42F7-8B45-E8E6FC226663

Q36934269-8A0389A0-A096-4F37-9C11-B3A643097F0E

Q36934269-EE26A292-0BAA-4D72-A1D9-FE317AB10DE5

P2860

Q36934269-1C19DF4D-2C7D-4E4A-B2BC-36B763B9558D

Q36934269-2A2C40C4-E9AE-4B33-9F83-B38370B53E7A

Q36934269-2C3DB885-336E-4016-8E60-8ADD072B5CBB

Q36934269-5B5C7457-ED65-46AD-976F-DF78FE5715F1

Q36934269-7E1B97FD-9D16-47F6-9ADD-B0199A14E40F

Q36934269-837CFEE7-CFFC-42A2-8B99-87EEA9244D07

Q36934269-91494DAA-CA52-4425-BE70-84084E4C55A1

Q36934269-A1446501-A419-4B74-B20F-027C500AC997

Q36934269-C3F12C70-8AB7-4FDC-887D-0D5A4ED8C9F1

Q36934269-D697C620-A40F-4255-940A-25691CDC1554

P304

Q36934269-603AE1BA-C2C8-4C8A-ADB5-CD9279198796

P31

Q36934269-E8591279-FEF0-4010-AA30-61B2F2FE6750

P356

Q36934269-5A6B951D-3357-42ED-AF92-AEBFE771C757

P407

Q36934269-344EE59F-2EF6-41EC-900C-91B4C4DAE149

P433

Q36934269-725B947D-3CFF-4858-9B82-8E9065ED588B

P478

Q36934269-D013D87B-F998-4667-B050-DC52AB8D96D1

P50

Q36934269-0F7D3665-CE66-491F-9C55-B199AB94E1E1

Q36934269-2BB6886F-62C7-4993-9E64-47822C7A7DD6

Q36934269-CB1BE103-5B6B-4775-B94D-C98219C0308E

P577

Q36934269-02DA1C1E-E472-48B7-B180-BA966782C393

P698

Q36934269-6AA7910F-0556-4717-8977-E8F50DC0A9EA

P921

Q36934269-440FC0C4-B0D7-4F61-B424-7321DE20EE96

P932

Q36934269-3CAC2954-85AC-467C-84A8-DF7668424A68

P356

JCO.2008.19.6550

P1433

Journal of Clinical Oncology

P1476

Multicenter study of decitabin ...... atient treatment (ADOPT) trial

@en

P2093

David P Steensma

http://www.w3.org/2001/XMLSchema#string

James L Slack

http://www.w3.org/2001/XMLSchema#string

Julie S Larsen

http://www.w3.org/2001/XMLSchema#string

Lucy A Godley

http://www.w3.org/2001/XMLSchema#string

Maria R Baer

http://www.w3.org/2001/XMLSchema#string

Michael T Cullen

http://www.w3.org/2001/XMLSchema#string

Rena Buckstein

http://www.w3.org/2001/XMLSchema#string

Sujata Arora

http://www.w3.org/2001/XMLSchema#string

P2860

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.

5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends.

DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.

Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

Cellular differentiation, cytidine analogs and DNA methylation.

P304

3842-3848

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.19.6550

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Hagop Kantarjian

Guillermo Garcia-Manero

P577

2009-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19528372

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

4879689

http://www.w3.org/2001/XMLSchema#string